BUSSINESS
사업분야
HOME > 사업분야 > 사업분야
사업분야
SERVICE1
PDX-AD: Using Aβ amyloid and p-Tau concentrations detected in saliva to develop a machine learning-based system for identifying individuals at high risk of dementia
The measurement of Aβ amyloid and p-Tau in saliva and the establishment of a robust validation system are vital for developing an accessible, non-invasive, and cost-effective diagnostic tool for early detection and monitoring of Alzheimer’s disease and other neurodegenerative disorders. This method could revolutionize the approach to dementia screening and care, enabling earlier intervention and better outcomes.
SERVICE2
Long-Term Monitoring of Aβ amyloid and p-Tau in saliva for early detection
- The ability to easily measure Aβ amyloid and p-Tau in saliva supports personalized healthcare approaches.
- By tracking biomarker levels over time, healthcare providers can tailor interventions and monitor treatment effectiveness more precisely.
- For early detection of individuals at high risk of dementia.
Detecting Aβ amyloid and p-Tau concentrations in saliva and integrating this data into a machine learning system offers a non-invasive, cost-effective method
- 쉽게 수정하실 수 있도록 메뉴얼이 준비되어 있습니다.
- 십분의일은 수준 높고 한 눈에 들어오는 디자인을 추구합니다.
- 다양한 레이아웃과 디자인이 준비되어 있습니다. 더 둘러보세요!
SERVICE3
Long-Term Monitoring of Biomarkers associated with Dementia
PDX-AD can complement or replace traditional invasive tests and is highly suitable for large-scale dementia screening. Machine learning models based on salivary biomarker data can improve prediction accuracy and support the development of personalized medical treatments for patients.
Continuous monitoring helps in understanding disease progression in asymptomatic individuals, aiding in the development of personalized prevention strategies.
Process for a mobile app-based healthcare service for early dementia prevention and health management.
